0 0 11 mesi fa
As a valuable partner focused on antibody-drug conjugates (ADCs) research and development, Creative Biolabs recently launched a powerful ADC payload called amatoxin based on their exclusive “DrugLnk” organic synthesis platform.
Antibody-drug conjugates (ADCs) are next-generation targeted anti-tumor agents, consisting of a monoclonal antibody with a cytotoxic payload drug via a small molecular linker. The toxic payload drug as an essential component of any therapeutic ADC plays a decisive role ... Maggiori informazioni

Seguici su Facebook

iAB member
Copyright 2019 - Spreaker Inc. a Voxnest Company - Crea un podcast - New York, NY